Combination therapy comprising SGLT inhibitors and DPP4 inhibitors

摘要

The present invention relates to combination therapy comprising a DPP4 inhibitor and an SGLT inhibitor. The combination of the present invention leads to increase plasma GLP-1 level and the combination is useful for prevention or treatment of conditions such as diabetes and diseases related to diabetes.

主权项

1. A method for increasing plasma active GLP-1 level comprising administering to a patient a therapeutically effective amount of an SGLT inhibitor and a DPP4 inhibitor, wherein the SGLT inhibitor is a compound selected from the group consisting of:
1-(β-D-Glucopyranosyl)-4-chloro-3-[5-(6-fluoro-2-pyridyl)-2-thienylmethyl]benzene or a pharmaceutically acceptable salt thereof; 1-(β-D-Glucopyranosyl)-4-chloro-3-[5-(6-fluoro-3-pyridyl)-2-thienylmethyl]benzene or a pharmaceutically acceptable salt thereof; 3-(4-Cyclopropylphenylmethyl)-4-fluoro-1-(β-D-glucopyranosyl)indole or a pharmaceutically acceptable salt thereof; and 3-(4 Cyclopropylphenylmethyl)-4,6-difluoro-1-(β-D-glucopyranosyl)indole or a pharmaceutically acceptable salt thereof and; the DPP4 inhibitor is a compound selected from the group consisting of: 3-[(2S,4S)-4-[4-(3-methyl-1-phenyl-1H-pyrazol-5-yl]piperazin-1-yl]pyrrolidin-2-ylcarbonyl)thiazolidine or a pharmaceutically acceptable salt thereof; Sitagliptin or a pharmaceutically acceptable salt thereof; and (2S)-2-cyano-1-[trans-4-(dimethylaminocarbonyl)cyclohexylamino]acetylpyrrolidine or a pharmaceutically acceptable salt thereof.